Cargando…
Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
[Image: see text] KRAS is mutated in ∼20% of human cancers and is one of the most sought-after targets for pharmacological modulation, despite having historically been considered “undruggable.” The discovery of potent covalent inhibitors of the KRAS(G12C) mutant in recent years has sparked a new wav...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2020
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453568/ https://www.ncbi.nlm.nih.gov/pubmed/32875077 http://dx.doi.org/10.1021/acscentsci.0c00411 |